{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:32:27Z","timestamp":1768869147839,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"DOI":"10.7759\/cureus.101833","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:55:39Z","timestamp":1768823739000},"source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin Cardiac Amyloidosis With Reduced Ejection Fraction in a 47-Year-Old Man: An Unusual Presentation"],"prefix":"10.7759","author":[{"given":"Mehdi","family":"Moujahid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idriss","family":"Allalat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouad","family":"Lamtai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Fellat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) cardiac amyloidosis","volume":"126","author":"Ruberg FL","year":"2012","unstructured":"Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012, 126:1286-300. 10.1161\/CIRCULATIONAHA.111.078915","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro A","year":"2018","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018, 18:s30-5. 10.7861\/clinmedicine.18-2-s30","journal-title":"Clin Med (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: An update on diagnosis and treatment","volume":"84","author":"Donnelly JP","year":"2017","unstructured":"Donnelly JP, Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med. 2017, 84:12-26. 10.3949\/ccjm.84.s3.02","journal-title":"Cleve Clin J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS)","volume":"43","author":"Damy T","year":"2022","unstructured":"Damy T, Kristen AV, Suhr OB, et al.. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS). Eur Heart J. 2022, 43:391-400. 10.1093\/eurheartj\/ehz173","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al.. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021, 42:1554-68. 10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore JD","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al.. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016, 133:2404-12. 10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer MS","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al.. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018, 379:1007-16. 10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"ref8","article-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed","author":"Dolgin M","year":"1994","unstructured":"Dolgin M, New York Heart Association Criteria Committee. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th ed. Little, Brown & Co, Boston; 1994."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini E","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, et al.. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005, 46:1076-84. 10.1016\/j.jacc.2005.05.073","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano A","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL, et al.. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016, 1:880-9. 10.1001\/jamacardio.2016.2839","journal-title":"JAMA Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2017.07.004","article-title":"Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment","volume":"28","author":"Siddiqi OK","year":"2018","unstructured":"Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018, 28:10-21. 10.1016\/j.tcm.2017.07.004","journal-title":"Trends Cardiovasc Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2007.01.012","article-title":"Non-invasive predictors of survival in cardiac amyloidosis","volume":"9","author":"Kristen AV","year":"2007","unstructured":"Kristen AV, Perz JB, Schonland SO, et al.. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail. 2007, 9:617-24. 10.1016\/j.ejheart.2007.01.012","journal-title":"Eur J Heart Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson MM","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, et al.. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020, 142:e7-e22. 10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors LH","year":"2003","unstructured":"Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003, 10:160-84. 10.3109\/13506120308998998","journal-title":"Amyloid"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams D","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, et al.. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018, 379:11-21. 10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson MD","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al.. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018, 379:22-31. 10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/457096-transthyretin-cardiac-amyloidosis-with-reduced-ejection-fraction-in-a-47-year-old-man-an-unusual-presentation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:55:39Z","timestamp":1768823739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/457096-transthyretin-cardiac-amyloidosis-with-reduced-ejection-fraction-in-a-47-year-old-man-an-unusual-presentation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.101833","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,19]]}}}